Antidepressant adult suicidality committee
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee will discuss the results of ongoing FDA meta-analyses of suicidality data from adult antidepressant trials during a Dec. 13 meeting. The panel, along with FDA's Pediatric Advisory Committee, reviewed data concerning the relationship between antidepressants and suicidal thoughts and actions in children and adolescents during two 2004 meetings (1"The Pink Sheet" Sept. 20, 2004, p. 3). The meeting will be held at the Hilton in Silver Spring, Md., beginning at 8 a.m....
You may also be interested in...
FDA Will Strengthen Antidepressant Warnings; “Black Box” Not Certain
FDA will require stronger warnings on antidepressants regarding the risk of pediatric suicidality following a Sept. 13-14 advisory committee review of the issue, but the agency is not yet ready to say that a "black box" will be necessary
US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: